How Does Dynavax Company Work and Make Money?

How does Company sell vaccines and license its adjuvant to generate revenue?

Company commercializes a hepatitis B vaccine and licenses its HEPLISAV-B adjuvant to partners, capturing margin from direct sales and royalties. In 2025 the company reported positive operating cash flow and growing vaccine uptake, signaling durable commercial traction.

Company's revenue mix blends high-margin product sales with scalable licensing fees; streamlined manufacturing and focused commercial spend improved margins and cash generation in 2025. See product detail: Dynavax Marketing Mix 4P

Company Name develops and commercializes vaccines and immune-enhancing adjuvants, notably the HEPLISAV-B adult hepatitis B vaccine and the CpG 1018 adjuvant, selling to healthcare providers, pharmacies, governments, and industry partners to boost vaccine efficacy and completion rates.

Core commercial offerings

Company Name is best known for HEPLISAV-B, a two-dose adult hepatitis B vaccine, and the CpG 1018 adjuvant platform licensed to partners for use in other vaccines and therapeutics.

Primary customers

Customers include US and international public health agencies, hospital systems, retail pharmacies, and biopharma firms licensing CpG 1018 for their vaccine pipelines.

Value delivered

Company Name delivers higher seroprotection – about 95% for HEPLISAV-B versus ~81% for legacy adult hepatitis B vaccines – and a faster two-dose schedule that reduces patient drop-off and increases completion.

Why customers choose it

Customers favor the product for faster series completion, higher efficacy, and the CpG 1018 adjuvant's ability to boost immune responses, which is attractive for partners seeking stronger vaccine candidates.

Company Name's business model mixes direct product sales, licensing/royalties, and partnership/co-development deals to monetize HEPLISAV-B and CpG 1018 across public and private channels.

Company Name core value proposition

Company Name sells a high-efficacy adult hepatitis B vaccine and an adjuvant platform that partners license to improve vaccine performance; revenue combines vaccine sales, adjuvant licensing, and milestone/royalty income.

• HEPLISAV-B two-dose adult hepatitis B vaccine
• Primary customers: public health agencies, pharmacies, biopharma partners
• Delivers faster completion and higher protection rates (~95%)
• Stands out via CpG 1018 licensing and differentiated clinical performance

What the Company Does and What Value It Delivers: Company Name addresses adult immunization gaps with HEPLISAV-B's two-dose, one-month regimen and licenses CpG 1018 to partners to boost vaccine efficacy and revenue streams; see a detailed analysis in Growth Strategy and Outlook of Dynavax Company

Dynavax SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Company Name develops and commercializes vaccines and adjuvants, selling HEPLISAV-B and licensing CpG 1018 to partners; it runs a US-focused commercial organization, outsources large-scale manufacturing to CMOs, and sells through health systems, retail pharmacies, and government procurement under recent 2024 – 2025 universal vaccination demand.

Operating model centered on vaccine commercialization

Company Name combines in-house commercial strategy with outsourced manufacturing, keeping a dedicated US sales force of roughly 150 reps to drive HEPLISAV-B adoption and manage key payer relationships.

Product and service delivery via clinical and retail channels

HEPLISAV-B is distributed through hospital systems, retail pharmacies (CVS, Walgreens), and government contracts; cold-chain distributors and wholesalers maintain temperature control to clinics and pharmacies.

Development and production through hybrid sourcing

R&D and life-cycle management stay in-house while large-scale vaccine and CpG 1018 production is handled by CMOs, enabling scale without heavy fixed-capacity spending.

Sales channels and distribution networks

Revenue flows via direct sales to health systems, retail pharmacy procurement, wholesaler-distributor networks, and licensing deals that generate royalties and milestone income.

Key assets, systems, and partnerships

Critical assets include the CpG 1018 adjuvant IP, HEPLISAV-B commercial approvals, CMO contracts, a 150-person sales team, and strategic partnerships for co-development and licensing.

Practical enabler: licensed adjuvant plus focused commercialization

The combination of proprietary CpG 1018 licensing and a lean commercial core lets Company Name monetize both direct vaccine sales and recurring royalty streams from partners using the adjuvant.

Company Name runs a focused, outsourcer-backed commercial engine that leverages CpG 1018 licensing and HEPLISAV-B sales to generate mixed revenue streams: product sales, royalties, and milestone payments.

How the Company Operates in Practice

Operations combine internal commercial leadership, targeted US sales, outsourced manufacturing, and partnership monetization of the CpG 1018 adjuvant to scale revenue without heavy capital intensity.

• Core model: direct HEPLISAV-B sales plus licensing of CpG 1018
• Delivery: hospital, pharmacy, and government procurement with cold-chain logistics
• Support: CMOs for manufacture; distributors for logistics; partners for co-development
• Efficiency driver: licensing royalties and CMO outsourcing reduce fixed-cost exposure

How the Company Operates: the company operates through a streamlined commercial infrastructure and a sophisticated manufacturing supply chain; it maintains a US field force of about 150, outsources production to CMOs, and uses distributors for cold-chain logistics, while pursuing life-cycle management of CpG 1018 into new vaccine combinations to boost licensing and royalty revenue – see Mission, Vision, and Core Values of Dynavax Company for related context.

Dynavax PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Company Name earns most revenue from HEPLISAV-B vaccine sales and long-term CpG 1018 adjuvant supply and license agreements; product sales to hospitals, clinics, and public buyers drove 2025 results. HEPLISAV-B premium pricing and >75 percent gross margins on vaccine sales funded pipeline spend while licensing and manufacturing deals added recurring, high-margin revenue.

Main revenue stream: HEPLISAV-B vaccine sales

HEPLISAV-B net product sales were the primary revenue source, exceeding $280,000,000 in fiscal 2025 as Company Name captured over 40% of the US hepatitis B market by doses sold. High margins and hospital/clinic procurement contracts made this the cash engine for operations and R&D funding.

Additional revenue streams: CpG 1018 licensing and supply

Company Name monetizes CpG 1018 via supply agreements, licensing fees, and royalties from partners developing vaccines (e.g., shingles, influenza), producing steady recurring revenue after pandemic-era spikes subsided.

Pricing and monetization model: premium product sales plus contract revenue

Revenue comes from premium-priced vaccine unit sales, fixed-price supply contracts, milestone payments, and license/royalty streams; public-sector tenders and private hospital procurement mix secures volume and pricing power.

What drives revenue most: product mix and market share

Scale of HEPLISAV-B sales and CpG 1018 partner penetration drive revenue; maintaining >40% US hepatitis B market share and expanding adjuvant licensing are key to sustaining growth and margin profile.

For more on ownership and structural context that affects commercial strategy, see Ownership of Dynavax Company

How Company Name monetizes its vaccine and adjuvant portfolio

Company Name turns clinical differentiation into premium sales and converts adjuvant technology into licensing and supply cash flows, producing a high-margin, low-dilution funding model for pipeline work.

• HEPLISAV-B vaccine sales: primary cash engine
• CpG 1018: licensing, supply agreements, and royalties
• Monetization model: premium unit pricing plus contract and milestone revenue
• Strongest driver: HEPLISAV-B market share and adjuvant partner uptake

Dynavax Business Model Canvas

• Complete Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

The Company's model depends on a differentiated vaccine-adjuvant pair, regulatory endorsements, and partner licensing to convert R&D into recurring revenue; key strengths are HEPLISAV-B uptake, CpG 1018 licensing, and a strong cash position, while risks include competitor scale, patent timelines, and pipeline concentration.

Clinical differentiation and regulatory tailwinds

HEPLISAV-B's two-dose schedule and the ACIP adult hepatitis B recommendation drive higher completion rates and steady demand, supporting higher per-dose pricing and market share versus multi-dose rivals.

Proprietary CpG 1018 adjuvant and partnership leverage

CpG 1018's inclusion in regulatory filings creates a high switching cost for partners and underpins licensing and royalty revenues from collaborations with larger vaccine makers and contract manufacturers.

Concentration and operational dependencies

Revenue is concentrated in HEPLISAV-B sales and CpG 1018 licensing; manufacturing capacity, reimbursement rates, and patent expiries are single points of failure that could compress margins if disrupted.

Durability in 2025 – 2026

As of 2026 the model looks durable: a > 600,000,000 cash balance supports commercialization and pipeline spending, HEPLISAV-B maintains market traction, and licensing dealflow diversifies revenue but competitive pressure from GSK/Merck keeps risk elevated.

The Company's revenue mix combines product sales, licensing/royalties, and milestone payments tied to CpG 1018 and HEPLISAV-B, with growing services income from manufacturing and supply agreements.

Why the business model works and what could weaken it

Dynavax Technologies converts a differentiated vaccine and proprietary adjuvant into recurring sales and licensing cash flows; loss of exclusivity, slower partner commercialization, or pricing/reimbursement cuts would materially weaken economics.

• HEPLISAV-B's clinical advantage boosts adoption and pricing
• CpG 1018 licensing generates royalties and milestone payments
• Manufacturing, patent life, and payer decisions are key constraints
• Model appears resilient in 2026 but exposed to large competitors

For historical context and milestones see this company overview: History of Dynavax Company

Dynavax Marketing Mix

• Covers Marketing Mix Analysis in Details
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔